Herbal Industry | Schedule T - Good manufacturing Practices | Unit 5 HDT 6th Semester
This lecture covers Unit 5 of Herbal Drug Technology for 6th Semester pharmacy students, focusing on the herbal industry in India, its present scope and future prospects, major plant-based companies, research institutions, and Schedule T (Good Manufacturing Practices) for Ayurvedic/herbal drug manufacturing.
Summary
The lecture begins with an introduction to herbal industries, defining them as establishments involved in the cultivation, processing, formulation, and marketing of herbal medicines. The instructor identifies well-known Indian herbal companies such as Himalaya, Dabur, Patanjali, Zandu, and Vaidyanath as prime examples, noting that these companies produce plant-based products and are heavily marketed to the public.
The present scope of the herbal industry is discussed across several dimensions: growing popularity due to minimal side effects compared to synthetic drugs, preference for natural and preventive healthcare, deep integration into Indian healthcare systems (Ayurveda, Siddha, Unani, Yoga, Naturopathy — collectively called AYUSH), significant market growth with India's herbal market estimated at $5.9 billion projected to reach $26.8 billion by 2030 at 8% CAGR, and strong government support through the Ministry of AYUSH.
Future prospects include rapid global market growth (estimated at $100–105 billion globally), increasing scientific validation of traditional herbal medicines (e.g., curcumin in turmeric), integration with modern healthcare for chronic lifestyle diseases like diabetes and hypertension, development of standardized formulations and novel drug delivery systems, improved bioavailability and dosing accuracy, and expanded export potential to the USA, Europe, and Asian countries.
The lecture then covers major plant-based Indian industries including Himalaya Herbals, Dabur, Patanjali, Aimil Pharmaceuticals, Baidyanath, Shri Shri Tattva, Zandu (part of Emami Group), Hamdard (established 1906, focused on Unani medicine), and Vicco Laboratories (known for turmeric-based products).
Research institutions working on medicinal and aromatic plants are also discussed, including CCRAS, CSIR-NBRI (Lucknow), CDRI (Lucknow), and others across cities like Jamnagar, Jaipur, Bengaluru, Kolkata, and New Delhi. Their roles include conservation of medicinal plants, scientific validation of traditional medicines, standardization, quality control, and documentation of traditional knowledge.
Finally, Schedule T under Drugs and Cosmetics Rules 1945 is explained as the GMP (Good Manufacturing Practices) framework for Indian Systems of Medicine (ASU — Ayurveda, Siddha, Unani). Key GMP components covered include: location and surroundings (pollution-free areas), building design (proper lighting, ventilation, smooth walls/floors), water supply (clean with regular testing), waste disposal, container cleaning, storage areas, working space adequacy, equipment suitability and maintenance, worker health and hygiene, medical services, batch manufacturing records, distribution records, product recall systems, market complaint records, quality control, and Standard Operating Procedures (SOPs).
Key Insights
- The instructor states that India's herbal medicine market, currently estimated at $5.9 billion, is forecast to reach $26.8 billion by 2030 at an 8% CAGR, while the global herbal drug industry overall is estimated at $100–105 billion for 2024–25.
- The instructor argues that traditional herbal knowledge directly accelerates new drug development — using the example of neem's traditional use leading scientists to investigate its active compounds, thereby enabling evidence-based formulations.
- The speaker points out that India uses nearly 8,000 medicinal plant species in its traditional and modern healthcare systems, positioning it as one of the richest countries in terms of medicinal and aromatic plant diversity.
- The instructor explains that Schedule T under the Drugs and Cosmetics Rules 1945 is the specific GMP framework mandating that Ayurveda, Siddha, and Unani medicines must be manufactured under controlled, hygienic, and standardized conditions to ensure safety, efficacy, and consistent quality.
- The speaker explains that Batch Manufacturing Records and Distribution Records are critical GMP requirements because they enable traceability — if a marketed product causes harm, authorities can identify which ingredients, workers, and processes were involved, and which distributors received that batch for potential recall.
Topics
Full transcript available for MurmurCast members
Sign Up to Access